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Background: The goal of periodontal regenerative therapies is
to reconstruct periodontal tissues such as bone, cementum, and
periodontal ligament cells (PDL). The need to establish pre-
dictable treatment modalities is important for reconstruction of
these tissues. The aim of this study was to determine the effects
of a low molecular extract of bovine bone protein (BP) contain-
ing bone morphogenetic proteins (BMPs) 2, 3, 4, 6, 7, 12, and
13, alone or in combination with platelet-derived growth factor
(PDGF) and/or insulin-like growth factor (IGF) on osteoblast dif-
ferentiation in vitro.
Methods: BP, mixed with a collagen matrix, was added to a
poly (DL-lactide-co-glycolide) polymer (PLG) and placed at
orthotopic sites in the skullcaps of Sprague-Dawleys rats. At day
28, rats were sacrificed for histological analysis. All sites treated
with the polymer/BP produced bone while control sites (without
BP) showed no bone formation. Having established the biologi-
cal activity of BP, in vitro studies were initiated using MC3T3-E1
cells, a mouse osteoprogenitor cell line. The ability of BP and
other growth factors to alter cell proliferation was determined by
Coulter counter, and differentiation was determined by Northern
analysis for specific genes.
Results: When compared with cells treated with 2% serum
alone, PDGF enhanced cell numbers at 10 and 20 ng/ml; IGF
produced no significant effect at these doses; and BP at 10 and
20 µg/ml decreased cell proliferation. Northern analysis revealed
that PDGF blocked gene expression of osteopontin (OPN) and
osteocalcin (OCN), while BP and IGF promoted gene expression
of bone sialoprotein (BSP) and OPN. The combination of BP and
IGF enhanced expression of OPN beyond that of either BP or IGF
alone. PDGF was able to block the effects of IGF on gene
expression, but not those of BP.
Conclusions: These results indicate that BP, PDGF, and IGF
influence cell activity differently, and thus raise the possibility
that combining factors may enhance the biological activity of
cells. J Periodontol 1999;70:1345-1354.
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A
n ultimate goal of periodontal
regenerative therapies is to
establish treatment modalities
that predictably reconstruct periodon-
tal tissues lost as a consequence of
disease. This requires formation of
bone, cementum, and a functional
periodontal ligament (PDL). A key for
reengineering these tissues is to first
ascer tain the necessary factors
required for their development. As
one approach, the studies described
here focus specifically on determining
the effects of agents on expression of
genes associated with osteoblasts
using a well-defined in vitro system.
This in vitro model utilizes MC3T3-E1
cells, a mouse osteoblast progenitor
cell line. Importantly, when MC3T3-
E1 cells in vitro are exposed to ascor-
bic acid and β-glycerol phosphate,
they differentiate along the osteoblast
pathway. This differentiation includes
expression of osteoblast-associated
genes, e.g., alkaline phosphatase
(ALP), bone sialoprotein (BSP),
osteocalcin (OCN), and osteopontin
(OPN) and secretion of a matrix
appropriate for promoting mineral
nodule formation.1,2 Studies using a
rat periodontal regenerative model
have shown that these same genes
are associated with bone formation in
vivo.3 Thus, these cells provide an
excellent system for initial screening
of agents to determine whether or not
specific factors can influence osteo-
blast differentiation.
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Attractive candidates for promoting osteoblast dif-
ferentiation include polypeptide growth factors4,5 and
bone morphogenetic proteins.6 The studies here
focused on determining the role of platelet-derived
growth factor (PDGF), insulin-like growth factor
(IGF), and a partially purified extract of bovine bone
(BP) containing a mixture of bone morphogenetic
proteins (BMPs), alone and in combination, in regu-
lating proliferation and gene expression in MC3T3-E1
cells. The rationale for selecting these factors was
based on several points, including: 1) the known abil-
ity of polypeptide growth factors to promote events
associated with wound healing including cell migra-
tion, cell proliferation, and extracellular matrix pro-
duction;7 2) existing evidence suggesting that
PDGF/IGF can act synergistically to promote peri-
odontal regeneration, bone formation, and cell prolif-
eration both in vitro8-11 and in vivo;12-14 and 3) the
known ability of bone morphogenetic proteins, such
as those present in demineralized freeze-dried bone,
to induce bone formation15,16 and also cementogene-
sis.17,18
PDGF containing two polypeptide chains as either
a homodimer (AA or BB) or a heterodimer (AB)
exhibits strong mitogenetic activity in many cell
types. The ability of PDGF to promote wound healing
has been attributed to its proliferative activity, where it
may function to increase the number of cells within
the local environment at a healing site. IGF-I and -II
are anabolic polypeptide growth factors structurally
related to insulin. IGFs, produced in bone cells and
stored in high concentrations within the bone matrix,
are considered to regulate bone cells through both
autocrine and paracrine pathways, resulting in an
increase in osteoblast maturation.19-21 IGF activity
and concentration at local sites have been shown to
be regulated by several other factors including
IGFBPs (IGF binding proteins), PDGF, and bone mor-
phogenetic proteins (BMPs). Interestingly, PDGF
appears to decrease expression of IGF mRNA in
osteoblasts, while BMPs increase expression of IGF
mRNA. Cell receptors for PDGF and IGFs have been
identified and, while different from each other, are
both tyrosine kinase signaling receptors.22-24
The BMPs, originally isolated from bone, belong to
the TGF-β superfamily and have a variety of functions
dependent on tissue location and developmental
stage.15,16,25-27 Studies to date provide convincing
evidence that BMPs are power ful inducers of
osteoblast differentiation in vitro28,29 and bone forma-
tion in vivo,17,30-32 and thus may have potential for
use in clinical situations where new bone formation is
required. BMPs act through specific threonine-serine
receptor kinases.
Previous in vitro and in vivo studies have demon-
strated that PDGF/IGF act synergistically to promote
periodontal regeneration, while data from in vitro
studies using BMP and IGF in combination suggest
that these 2 factors act synergistically to promote
osteoblast differentiation.33,34 This prompted us to
determine whether or not combinations of PDGF/
IGF/BP would prove to be useful for promoting peri-
odontal regeneration. As a first step, the studies here
focused on examining the effect of PDGF, IGF, and/or
BP in various combinations on osteoblast activity in
vitro. Factors that can enhance mineral tissue forma-
tion in vitro have potential for clinical use to promote
both root mineralization and bone formation as
required subsequent to loss of periodontal tissues.
Results of studies here indicate that both IGF and BP
promoted osteoblast differentiation as measured by
expression of BSP, OPN, and OCN mRNA in MC3T3-
E1 cells, with an additive effect when used in combi-
nation. In contrast, PDGF promoted proliferation in
MC3T3-E1 cells and blocked dif ferentiation of
osteoblasts as measured by decreased expression of
OCN mRNA. Furthermore, when added with IGF,
PDGF blocked the ability of IGF to induce expression
of BSP, OPN, and OCN mRNA.
MATERIALS AND METHODS
Assay for Bovine Bone Protein Activity
BP was obtained as a dry lyophilized powder from a
commercial source.‖ 35-37 The biological activity was
assessed using a rat orthotopic calvaria model. BP
was prepared by dissolving 35 µg of BP in 35 µl of
10 mM HCl solution. This was added to 5 mg of
lyophilized collagen¶ and allowed to soak into the col-
lagen matrix. The resulting BP/collagen mixture was
lyophilized and then added to 45 mg of a 50:50 poly
(DL-lactide-co-glycolide) polymer (PLG) with an
inherent viscosity of 0.17 dl/g.#
Adult Sprague Dawley rat calvaria were exposed
via a midline incision extending from the nasal bone
to the mid-saggital crest and the skullcap was
exposed with blunt dissection. The periosteum was
removed from the internal flap surface and the poly-
mer implant containing the lyophilized BP/collagen
matrix was placed at the orthotopic site. Incisions
were closed with 4-0 silk sutures. The animals were
sacrificed at day 28 and their skullcaps surgically
removed and processed for histological evaluation.
Six micron step serial sections were made through
the implant area and slides were analyzed for the
overall amount of bone formation within the implant
histomorphometrically.
Culturing of MC3T3-E1 Cells
MC3T3-E1 cells originally obtained from Dr. M.
Kumegawa (Meikai University, Sakado, Japan) were
‖ Colorado Biogenix, Denver, CO.
¶ Bovine Type 1 Collagen, ReGen Biologics, Redwood City, CA.
# Birmingham Polymers, Inc., Birmingham, AL.
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maintained as previously described.1 Briefly, cells were
grown in α-modified Eagle’s medium (α-MEM)** and
10% fetal bovine serum (FBS) containing 100 U/ml of
penicillin and streptomycin. Cells were passaged every
4 to 5 days and not used beyond passage 15. For cell
proliferation assays and for Northern analyses, cells
were cultured in media (mineralization media) contain-
ing 50 µg/ml ascorbic acid†† and 10 mM β-glycero-
phosphate†† to induce osteoblastic differentiation and
mineralization, respectively.38
Cell Proliferation
For proliferation assays, cells were plated in 24-well
dishes, at 5,000 cells/ml in triplicate. For these stud-
ies, cells were exposed to mineralization media con-
taining 2% FBS plus growth factors, unless stated
otherwise.
In order to determine appropriate doses of growth
factors to use for gene expression studies, cells were
exposed to varying doses of PDGF and/or IGF over
an 8-day period, and cell number determined over
time. In a separate experiment, the effect of BP on
cell number also was examined.
For these studies, initial doses used were PDGF-BB
or IGF-I at 1, 10, or 20 ng/ml; PDGF/IGF at 1, 10, or
20 ng/ml each; or BP at 1, 10, and 20 µg/ml. These
initial doses were selected based on previous in vitro
studies from our laboratory group, as well as oth-
ers.8,39 After the 24-hour adhesion period, medium
was removed and replaced with appropriate agents
plus 2% FBS. Medium, containing factors, was
replaced on day 3 and 6. Appropriate controls
included cells exposed to media with 2% serum only
(without ascorbic acid or 10 mM β-glycerophos-
phate), referred to in the text as negative control
(CN), as well as cells exposed to media with 2%
serum plus mineralization, i.e., 50 µg ascorbic acid
plus 10 M β-glycerophosphate, referred to in the text
as vehicle control. Cells exposed to mineralization
media containing 10% serum are referred to as posi-
tive controls. These same controls were used for
Northern analysis of MC3T3-E1 cells after exposure
to specific factors (see below). Cells were harvested
on day 3, 6, and 8 and cell number determined by
Coulter counter. PDGF and IGF were purchased from
a commercial source.‡‡
Northern Blot Analysis
For Northern analyses, cells were plated in 100 mm
dishes at an initial density of 50,000 cells/cm2. After a
24-hour attachment period, media were changed to
mineralization media, 10% FBS or 2% FBS, supple-
mented with appropriate growth factors unless other-
wise indicated. Specifically, cells were exposed 
to PDGF (10 ng/ml), IGF (10 ng/ml), or BP (10
µg/ml), or to combinations of these factors at these
same doses, i.e., PDGF/IGF or PDGF/BP or IGF/BP or
PDGF/IGF/BP. RNA was isolated at day 8 and 16. In
some experiments, BP was added after exposure of
cells to IGF, PDGF, or IGF/PDGF for 6 days. RNA was
isolated using the procedure of Xie and Rothblum.40
Briefly, for Northern analyses, total RNA was isolated
using guanidinium isothiocyanate, sodium citrate,
sodium acetate, phenol and chloroform extraction;
quantitated by spectroscopy at 260 nm; elec-
trophoresed (10 to 20 µg) on 1.2% agarose formalde-
hyde gels; and transferred to nylon membranes.
The following cDNA probes were hybridized with the
immobilized RNA: mouse osteopontin (OPN),41 mouse
bone sialoprotein (BSP),42 human osteocalcin
(OCN),43 bovine type I collagen (α1I),
44 and osteoblast-
specific transcription factor 2 (OSF2/Cbfa1).45 GAPDH,
a housekeeping gene, or ethidium bromide stained gels
were used to determine relative RNA loading.
Statistical Analysis
For statistical analysis, one-way analysis of variance
(ANOVA) and Tukey-Kramer multiple comparison
tests were performed.
RESULTS
An orthotopic rat calvaria model was used to verify
that BP had biological activity. As shown in Figure 1,
BP promoted bone formation in this model system,
confirming that the BP material had biologic activity.
All sites treated with the polymer containing the
BP/collagen matrix showed substantial bone forma-
tion. No control site treated with collagen/polymer
matrix without BP showed bone formation.
Next, to determine the effects of IGF, PDGF, and
BP on proliferation of MC3T3-E1 cells, cell counts
were done at various time points over an 8-day
period. BP at 1 to 20 µg resulted in a decrease in cell
number at day 8 when compared with vehicle control
(2%) and an increase in cell number when compared
with negative control (CN) (Fig. 2A). At day 8, PDGF
at 10 ng/ml and 20 ng/ml enhanced cell number
when compared to control cells – both vehicle control
(2%) and negative control (CN) (Fig. 2B). No signifi-
cant effect on cell number was noted in cells exposed
to 1 ng/ml PDGF. In contrast, IGF at all doses exam-
ined here (1 to 20 ng/ml) had no significant effect on
cell number beyond that seen for both vehicle control
(2%) and negative control (CN) (Fig. 2C).
Existing evidence that PDGF and IGF in combina-
tion have a synergistic effect on cell proliferation10,13
prompted us to next examine whether such an effect
would be obtained with MC3T3-E1 cells. As shown in
Figure 2D, MC3T3-E1 cell number was increased by
** Gibco BRL, Gaithersburg, MD.
†† Sigma Chemical Co., St. Louis, MO.
‡‡ R&D Systems, Minneapolis, MN.
PDGF/IGF combination when compared with 2% FBS
control cells, but this effect was not greater than that
noted for cells exposed to PDGF alone, at comparable
doses (Fig. 2B).
As a positive control, cells were exposed to miner-
alization media plus 10% FBS, and such cells exhib-
ited increased cell numbers when compared with all
other conditions. Statistical analyses at day 8 are
shown in Table 1.
Northern Analysis
For analysis of genes expressed by MC3T3-E1 cells
exposed to the various agents, doses used were as fol-
lows: PDGF 10 ng/ml; IGF 10 ng/ml; BP 10 µg/ml;
PDGF/IGF 10 ng/ml each; PDGF/BP (10 ng/ml/
10 µg/ml); IGF/BP (10 ng/ml/10 µg/ml); and
PDGF/IGF/BP (10 ng/ml/10 ng/ml/10 µg/ml). These
doses were selected to maintain consistency with the
proliferation studies. In most experiments, cells were
exposed to agents for the duration of the experiment, 8
days, with media changes every 3 to 4 days as
described above.
OCN/BSP
As shown in Figure 3, PDGF blocked expression of
OCN, a gene associated with osteoblast differentia-
tion, when compared with vehicle control (2%). Cells
exposed to BP and IGF exhibited enhanced expres-
sion of BSP compared to vehicle control (2%).
PDGF’s inhibitory effect on OCN
expression was noted in cells
exposed to PDGF/IGF combination.
In contrast, PDGF’s inhibitory effect
on OCN was not as prominent in
cells exposed to the combination of
PDGF/BP or PDGF/IGF/BP (P/I/BP).
OPN
As shown in Figure 4, the effects of
these agents on OPN expression were
more dramatic. Both IGF and BP pro-
moted OPN mRNA when compared
with the vehicle control (2%).
Furthermore, the combination of
IGF/BP resulted in an even greater
promotion of OPN mRNA levels.
Interestingly, PDGF blocked IGF-
mediated OPN mRNA (PDGF/IGF
lane), while PDGF was not able to
alter BP-mediated OPN mRNA ex-
pression (PDGF/BP lane). In addition,
the additive effect of IGF/BP on
OPN mRNA expression was blocked
by PDGF (P/I/BP lane). Results at day
16 were comparable to those at day 8
(data not shown).
OPN Pulse Experiments
The next series of experiments were designed to
determine whether an even greater effect on
osteoblast differentiation would be observed if cells
were exposed to growth factors early on, with BP
added at a later stage (Fig. 4). For these experiments,
cells were exposed to IGF (10 ng/ml) or PDGF (10
ng/ml) or PDGF/IGF (10 ng/ml/ 10 ng/ml) for the
total duration of the experiment, 8 days, with the
addition of BP (10 µg/ml) the last 2 days. On day 8,
RNA was extracted and transcripts for OPN deter-
mined by Northern analysis. No differences in gene
expression were noted between exposure of cells to
IGF/BP for 8 days (IGF/BP lane) versus adding BP on
day 6 (I/BP day 6 lane). Similarly, exposing cells to
PDGF/BP for 8 days (PDGF/BP lane) versus adding
BP on day 6 (P/BP day 6 lane) gave comparable
results. PDGF’s inhibitory effect on OPN mRNA
expression was noted in PDGF/IGF/BP treated cells
(P/I/BP lane), even after addition of BP on day 6
(P/I/BP day 6 lane).
Osf2
Studies by Ducy et al.45 have identified Osf2/Cbfa1
(osteoblast specific transcription factor/core-binding
factor) as an osteoblast-specific transcription factor
and more specifically as a regulator of osteoblast dif-
ferentiation. Thus, as a next step, the effect of expos-
ing cells to PDGF, IGF, and BP on expression of Osf2
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Figure 1.
Bone formation in a polymer implant containing bone protein at an orthotopic site in adult Sprague
Dawley rats. SK = skull (parietal bone); NB = new bone formation in the implant (original
magnification × 16).
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was determined. As seen in
Figure 5, BP and IGF did not
affect expression of Osf2
mRNA, while PDGF inhibited
Osf2 expression when com-
pared with the vehicle control
cells (2%). Cells exposed to the
combination of PDGF and IGF
still exhibited decreased levels
of Osf2 transcripts, while PDGF
was not able to completely
block Osf2 mRNA noted in
cells exposed to BP. Also, cells
exposed to 10% FBS exhibited
lower levels of Osf2 mRNA
when compared with cells
exposed to 2% FBS.
DISCUSSION
The studies here were designed
to determine the effects of IGF,
PDGF, and BP, alone and in
combination, on osteoblast dif-
ferentiation, using an in vitro
model system. Furthermore, it
was anticipated that the in vitro
model could serve as an assay
for screening agents for their
ability to promote osteoblast
differentiation prior to initiating
more costly in vivo studies with
these agents.
A well-characterized mouse
osteoblast progenitor cell line,
MC3T3-E1, was used for these
studies. Importantly, when these
cells are cultured in the pres-
ence of ascorbic acid, they are
stimulated to differentiate along
the osteoblast pathway.1,2 With
onset of differentiation,
there is a cessation of cell
replication, secretion of a
type I collagen-associated
extracellular matrix, and an
upregulation of markers of
osteoblast differentiation.
Thus, in the presence of
ascorbic acid, these cells
are induced to express
mRNA for BSP and OCN,
known markers for the
osteoblast phenotype. BSP,
a glycoprotein selective to
mineralized tissues, has
been implicated as having a
Figure 2.
Effect of PDGF, IGF, and BP on cell proliferation. Cells were plated at a density of 5,000 cells/ml and allowed
to adhere overnight. On the following day, mineralization media with appropriate growth factors were
added. Media were changed on day 3 and 6 and cells were harvested for cell counts on day 3, 6, and 8.
A. BP; B. PDGF; C. IGF; D. PI (PDGF/IGF 10 ng/10 ng).
Table 1.
Effect of PDGF, IGF and BP on Cell Proliferation; Statistical 
Analysis at Day 8
Treatment
Controls BP PDGF IGF PDGF/IGF
10 µg 20 µg 10 ng 20 ng 10 ng 20 ng 10 ng 20 ng
Vehicle (2%) * † * † NS NS * †
Negative (CN) † † † † NS NS † †
NS = not significant (P >0.05).
* P <0.01; † P <0.001.
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role in initiation of biomineralization.46-52 OCN, a hor-
monally regulated calcium-binding protein selective to
mineralized tissues, may play a role in early phases of
mineralization and in regulation of crystal growth.45
MC3T3-E1 cells also express OPN, although the exact
function for this protein in bone cells is less defined
than that of BSP or OCN. OPN is expressed by a vari-
ety of tissues,53 where in mineralized tissues, sug-
gested role(s) for OPN includes a regulator of crystal
growth and a promoter of cell migration to and attach-
ment at sites of bone formation and/or resorption.
The data presented here indicate that both IGF and
BP promote osteoblast differentiation as measured by
increased expression of osteoblast-specific
markers, while PDGF inhibits differentiation of
MC3T3-E1 cells along the osteoblast pathway.
Furthermore, when IGF-stimulated cells also
are exposed to PDGF, expression of osteoblast-
specific markers induced by IGF is blocked. In
contrast, PDGF was not able to block BP-
induced expression of osteoblast-specific
markers. When BP was added in combination
with IGF, the increased expression of OPN, OC
and BSP transcripts was still noted, where an
additive effect on OPN mRNA expression was
detected in these cells when compared with
cells treated with either BP or IGF alone. This
additive effect on OPN transcripts may prove
to have clinical significance. For example,
while highly speculative, agents that regulate
crystal growth,53 such as OPN, may provide an
appropriate balance between mineral forma-
tion and PDL attachment, thus preventing
ankylosis, as has been reported with use of
various other osteoinductive factors.
Interestingly, at the time we noted this addi-
tive effect on OPN mRNA expression, two
papers appeared supporting this finding. Yeh et
al.33 demonstrated that BMP-7/OP-1 and IGF-I
acted synergistically to promote [3H] thymidine
incorporation, alkaline phosphatase activity,
PTH-dependent cAMP level, and bone nodule
formation, using primary cultures of fetal rat
calvaria cells, where maximal synergy was
noted when they were added simultaneously.
They did not report on the effects of these fac-
tors on OCN, BSP, or OPN mRNA levels. In
another study, Hayden et al.54 demonstrated
that BMP-7 stimulates IGFBP-3 production in
human osteosarcoma cells predominantly by
promoting the production of IGFBP-3 nuclear
transcripts. The importance of this activity to
BMP-7’s ability to promote differentiation
remains to be established.
Based on previous reports indicating that
PDGF/IGF in combination promote periodontal
regeneration,13,14,55-57 we were surprised that the com-
bination of PDGF/IGF blocked expression of genes
associated with osteoblasts. However, the positive
effects of PDGF seen at sites of wound healing are
attributed to its ability to promote cell migration and
proliferation, thus establishing a critical mass of cells at
a local site.8-10,58-64 In fact, several studies report that
PDGF, while promoting cell replication, inhibits
osteoblast differentiation.22,65-67 Furthermore, Hock
and Canalis22 demonstrated that PDGF decreased IGF
mRNA in osteoprogenitor cells and suggested that this
effect may, in part, explain PDGF-mediated inhibition
of osteoblast differentiation. Thus, our studies support
Figure 3.
Effect of PDGF, IGF, and BP on expression of BSP and OCN mRNA in MC3T3-E1 cells.
Cells were exposed to agents for 8 days and then RNA extracted for Northern blot
analyses. IGF (10 ng/ml); PDGF (10 ng/ml); BP (10 µg/ml) - same dose used alone or
in combination studies. 18S RNA is shown to indicate relative loading of RNA.
Figure 4.
Effect of PDGF, IGF, and BP on expression of OPN mRNA in MC3T3-E1 cells. Doses
used were the same as for experiment shown in Figure 3. Note: where lane is day 6,
cells were exposed to either PDGF for 8 days with addition of BP on day 6 (P/BP day
6); or to IGF for 8 days with addition of BP on day 6 (I/BP day 6); or PDGF/IGF for 8
days with addition of BP on day 6 (P/I/BP day 6). 18S RNA is shown to indicate
relative loading of RNA.
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this finding where we show PDGF, but not IGF or BP,
promoted proliferation of MC3T3-E1 cells, but blocked
osteoblast differentiation. This result prompted us to
design experiments to determine whether osteoblast
differentiation would be enhanced if cells were exposed
to PDGF or IGF or PDGF/IGF for 6 days, followed by
BP. As seen in Figure 4, this treatment did not enhance
gene expression beyond that noted in cells continually
cotreated with BP/IGF. Moreover, addition of BP at day
6 did not counteract the inhibitory effect of PDGF on
IGF’s abilities to promote expression of specific genes.
This may be attributed to PDGF’s ability to block IGF
transcripts, as well as the noted ability of PDGF to reg-
ulate IGF binding proteins.23,24 It is clear from the
results presented here and reported by others22 that
PDGF inhibits osteoblast differentiation. This does not
rule out the possibility that PDGF may be of value in
regenerative procedures. For example, PDGF may act
early on in the regenerative process to promote cell
migration and/or cell replication, prior to addition of
factors that subsequently promote osteoblast differenti-
ation. The inability to demonstrate an additive effect on
expression of osteoblast-associated transcripts by
using PDGF followed by BP in the studies described
here may be attributed to several factors. Those factors
include: 1) doses selected may be inappropriate for
observing additive effects; 2) duration of exposure to
BP or IGF, e.g., in the pulse study; here, cells were
treated with PDGF or IGF for 6 days, followed by BP for
2 days; longer exposure to these later factors and also
removal of PDGF may have resulted in more impres-
sive results; 3) serum itself may alter activity of added
PDGF and IGF; and 4) cell type selected for studies. It
is well known that activity of growth factors is depen-
dent on stage of cell differentiation, as well as cell phe-
notype. Therefore, it is possible that with an alternative
experimental design, an additive effect would have
been seen when using PDGF in combination
with BP and/or IGF.
In contrast to PDGF, BP and IGF pro-
moted expression of transcripts associated
with the osteoblast phenotype. The BP used
here is an extract of bovine bone and con-
tains BMP-2, -3, -4, -6, -7, -12, and -13 with
virtually no IGF or PDGF.35 Thus, it was
anticipated that BP would promote
osteoblast differentiation. Early studies
directed at identifying inducers of osteoblast
differentiation in bone established that bone
contained “bone morphogenetic proteins
(BMPs)” that were capable of inducing endo-
chondral bone formation in vivo and carti-
lage in vitro.68-70 Subsequent studies have
resulted in identification of several BMPs,
where it is now recognized that in addition to
their critical role in mineralized tissues,15,26,27
they are widely distributed in other tissues as well and
have several other functions including acting as signal-
ing molecules in epithelial-mesenchymal interactions
during early organogenesis.71-75 In vitro studies using
recombinant BMPs have demonstrated that BMP-2, -4,
-6, and -7 are potent inducers of osteoblast differentia-
tion.29,33,76-81 In vivo studies have reinforced these
findings, demonstrating that BMPs promote regenera-
tion of bone and also periodontal tissues including
bone, cementum, and periodontal ligament, with
reported risk of accompanying ankylosis.18,30,32,56,82-85
The material used in our studies was extracted under
conditions that are selective for BMPs. Studies were
conducted to first demonstrate biological activity and
second, to demonstrate consistency from batch to
batch. As shown here, this material can induce bone
formation in vivo and induce osteoblast differentiation
in vitro, and these findings were reproducible.
In order to further define the mechanism(s) con-
trolling the activities of PDGF, IGF, and BP on bone
activity, expression of Osf2 transcripts was deter-
mined in cells exposed to PDGF and/or IGF and/or
BP. Osf2 is considered an osteoblast-specific tran-
scription factor. When added to C3H10T1/2 fibro-
blasts, in vitro BMP-7 has been shown to promote
expression of Osf2 mRNA, followed by expression of
transcripts for osteoblast specific markers.45 As shown
in Figure 5, PDGF blocked expression of Osf2 mRNA,
while IGF and BP maintained Osf2 mRNA levels in
MC3T3-E1 cells. Thus, the effect of specific factors on
Osf2 mRNA expression may serve as an indicator of
their ability to promote osteoblast differentiation.
In summary, the studies here demonstrate that BP
is a potent inducer of osteoblast differentiation and
may act synergistically with IGF to promote
osteoblast differentiation. Further studies, including
the use of various doses of BP/IGF and/or PDGF in
Figure 5.
Effect of PDGF, IGF, and BP on Osf2 mRNA in MC3T3-E1 cells. For these experiments,
cells were treated as described in Figure 3. GAPDH is shown to indicate relative
loading of RNA.
vivo and in vitro, are warranted to determine if there
are any benefits in using these factors in combination
for periodontal regenerative procedures.
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